程序性死亡受体-1/其配体1单抗联合放射治疗的抗肿瘤免疫机制

The antitumor immunological mechanism of programmed death 1/programmed death ligand 1 monotherapy combined with radiotherapy

免疫治疗可通过激活或者增强机体抗肿瘤免疫功能杀伤肿瘤细胞或抑制肿瘤的发生发展;免疫卡控点分子程序性死亡受体-1(PD-1)与其配体PD-L1、PD-L2结合,抑制T淋巴细胞功能,使肿瘤细胞逃避免疫应答;放射治疗可杀伤肿瘤细胞,同时增强和激活机体的固有和适应性抗肿瘤免疫应答。放疗联合PD-1/PD-L1单抗能够增强抗肿瘤免疫应答、促进肿瘤细胞凋亡,发挥协同抗肿瘤作用。

Immunotherapy can kill tumor cells and inhibit tumor development by activating and enhancing anti-tumor immune function. The immuno-controlled molecular programmed death 1 (PD-1) binds with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), inhibits the function of T lymphocytes, and makes tumor cells evade immune response. Radiotherapy can kill tumor cells while enhancing and activating the innate and adaptive anti-tumor immune response. Radiotherapy combined with PD-1/PD-L1 monoclonal antibody can enhance the anti-tumor immune response, promote the apoptosis of tumor cells, and exert a synergistic anti-tumor effect.